AA 1.0-ref | AT | OR for ATvsAA (95% CI) | p-value | A 1.0-ref | T | OR for TvsA (95% CI) | p-value | |
---|---|---|---|---|---|---|---|---|
Malignancy | 3 (6.5) | 44 (93.5) | 5.3 (1.1–26) | 0.05 | 50 (53.2) | 44 (46.8) | 1.5 (0.7–3) | 0.3 |
Benign | 11 (27) | 30 (73) | 52 (62.5) | 30 (37.5) | ||||
Metastasis | 10 (13.5) | 64 (68.5) | 1.7 (0.4–7.4) | 0.4 | 84 (56.8) | 64 (43.2) | 1.2 (0.5–2.7) | 0.7 |
No metastasis | 3 (21.4) | 11 (78.6) | 17 (60.7) | 11 (39.3) | ||||
Right | 7 (17.1) | 34 (82.9) | 0.7 (0.2–2.7) | 0.6 | 48 (58.5) | 34 (41.5) | 1.1 (0.6–2) | 0.8 |
Left | 6 (13) | 40 (87) | 52 (56.5) | 40 (43.5) | ||||
HER 2 positive | 6 (11.3) | 47 (88.7) | 2.3 (0.6–8.5) | 0.2 | 59 (55.7) | 47 (44.3) | 0.8 (0.4–1.6) | 0.5 |
HER 2 negative | 5 (22.7) | 17 (77.3) | 27 (61.4) | 17 (38.6) | ||||
PR positive | 8 (14.3) | 48 (85.7) | 1.1 (0.3–4.8) | 0.87 | 64 (57.1) | 48 (42.9) | 0.97 (0.5–2) | 0.9 |
PR negative | 3 (15.8) | 16 (84.2) | 22 (57.9) | 16 (42.1) | ||||
ER positive | 8 (13.3) | 52 (86.7) | 1.6 (0.4–7) | 0.5 | 68 (56.7) | 52 (43.3) | 0.87 (0.4–1.97) | 0.7 |
ER negative | 3 (20) | 12 (80) | 18 (60) | 12 (40) |